On September 25-27, 2017 in Arlington, VA, delegates gained insight from FDA members and peers on how to improve recall strategies from start to finish.
"Pharmaceutical recalls increased 28% in Q4 to 83, the highest level since Q3 2014. Recalled united jumped 192% to more than 25.1 million - The highest since Q2 2015 and the third highest since Q1 2012."
-Stericycle Recall Index Q4, 2016
Sessions included in this compendia are:
FDA Regulatory Requirements, Expectations and Trends by Israel Santiago of CDER/Office of Compliance, FDA
Mobilize and Deploy a Field-Based Team During a Recall by Hillary Medina of Novasyte
Senior-Level Think Tank - Assessment Leading into a Recall by Pearley Bhambri of Hill-Rom
Recall Fundamentals and How to Improve Recall Strategies from Start to Finish by Sonali Gunawardhana of Wiley Rein LLP
Ensure Timely and Effective Recall Communication to Minimize the Iimpacts on Brand and Reputation by Maureen Bernier of DAPO, Recall Branch
Implement Successful Execution Strategies for Voluntary Recalls by Lavinia Marinescu-Pederson of Novo Nordisk